Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of March 2022. The report details a material event involving a breach of a prior underwriting agreement with Aegis Capital Corp. and the subsequent resolution through a waiver and release agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figure disclosed relates to a new financing instrument:
- Convertible Promissory Note: $2,804,848.00 principal amount issued to Streeterville Capital, LLC on March 14, 2022.
- Breach Fee Payment: A fee was paid to Aegis Capital Corp. on March 22, 2022, to resolve a contractual breach; the specific dollar amount of this fee is not disclosed in the text.
Material Changes
The primary material change involves the Company's capital raising activities and contractual obligations:
- New Financing: The Company entered into a securities purchase agreement for a convertible promissory note with Streeterville Capital, LLC.
- Contractual Breach: This new transaction was deemed a breach of Sections 4.18 (Right of First Refusal) and 4.19 (Lock-up/Prohibition on Issuance) of the January 2022 Underwriting Agreement with Aegis Capital Corp.
- Resolution: A waiver and release agreement was executed on March 21, 2022. Aegis waived claims against the Company, and Sections 4.18 and 4.19 of the original Underwriting Agreement were struck in their entirety.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future business operations. The primary risk disclosed is the legal and financial consequence of breaching the prior underwriting agreement, which was mitigated by the payment of a fee and the removal of restrictive covenants.
Investor Verification Checklist
- Verify the exact amount of the fee paid to Aegis Capital Corp. on March 22, 2022, as it is not explicitly stated in this filing.
- Review the terms of the $2,804,848 convertible promissory note issued to Streeterville Capital, LLC, including interest rates, conversion price, and maturity date.
- Confirm the current status of the Company's cash position following the issuance of the note and the payment of the breach fee.
- Assess the impact of removing the "Right of First Refusal" and lock-up provisions on future capital raising flexibility.